Table 1.
Clinical and laboratory data of 14 Patients with Post-trans fusion hepatitis
| Patient | Age (yr)/gender | Peak ALT (IU/L) | Hepatitis |
| Unscreened Blood | |||
| SYS | 58/F | 1043 | HCV |
| CLT | 66/M | 527 | HCV |
| LCSG | 74/F | 264 | HCV |
| PTT | 76/M | 109 | HCV, TTV |
| SGM* | 43/M | 93 | HCV |
| LWG | 67/M | 257 | HCV, HGV |
| STS | 60/M | 455 | HCV, HGV, TTV |
| CSPC** | 48/F | 218 | HBV, CMV |
| CST | 30/M | 236 | CMV, HGV |
| LYY | 13/F | 103 | TTV |
| CSG | 64/M | 159 | 159 |
| Screened Blood | |||
| CPL | 65/F | 645 | CMV, TTV |
| HWL | 65/F | 541 | CMV |
| CHL*** | 63/M | 101 | HBV |
*
Patients were treated with interferon alfa 2b;
**
HBsAg ( + ), HBeAg ( - ), anti-HBe ( + ), anti-HDV ( - ); ***HBsAg ( + ), HBeAg ( + ), anti-HBe ( - ), anti-HDV ( - ); #Positive for TTV DNA before transfusion.